))
Highlights from 2024 World Conference on Lung Cancer (Meeting Mic Re-Release)
Manage episode 450145700 series 3560286
Вміст надано Healio, Shikha Jain, and MD. Весь вміст подкастів, включаючи епізоди, графіку та описи подкастів, завантажується та надається безпосередньо компанією Healio, Shikha Jain, and MD або його партнером по платформі подкастів. Якщо ви вважаєте, що хтось використовує ваш захищений авторським правом твір без вашого дозволу, ви можете виконати процедуру, описану тут https://uk.player.fm/legal.
In this special crossover episode of Oncology Overdrive, we bring you Healio coverage from the 2024 World Conference on Lung Cancer, as well as Healio’s top headlines from the meeting. With insights from Benjamin P. Levy, MD, and top headlines from the conference, Meeting Mic is your on-the-go source for highlights, pearls, and perspectives across all specialties.
Benjamin P. Levy, MD, discusses key takeaways from the meeting. 0:49
Read the full coverage here:
Ivonescimab extends PFS vs. pembrolizumab in advanced NSCLC, may be ‘a new standard’
Source: Zhou C, et al. Abstract 2700. Presented at: IASLC World Conference on Lung Cancer; Sept. 7-10, 2024; San Diego.
Perioperative nivolumab improves outcomes in resectable NSCLC
Source: Forde PM, et al. Abstract 3589. Presented at: IASLC World Conference on Lung Cancer; Sept. 7-10, 2024; San Diego.
Despite progress, barriers to lung cancer biomarker testing persist
Source: Smeltzer M, et al. Abstract 3000. Presented at: IASLC World Conference on Lung Cancer; Sept. 7-10, 2024; San Diego.
We’d love to hear from you! Send your comments/questions to Dr. Jain at [email protected]. Follow Healio on X and LinkedIn: @HemOncToday and https://www.linkedin.com/company/hemonctoday/. Follow Dr. Jain on X: @ShikhaJainMD.
Disclosures: Jain reports no relevant financial disclosures. Healio could not confirm relevant financial disclosures for Levy at the time of posting.
100 епізодів
Поширити
